Business News • PR NewsWire • Ariceum Therapeutics Launches with EUR 25M Series A to Advance Lead Asset, Satoreotide, for the Treatment of Low- and High-Grade Neuroendocrine Cancers

Ariceum Therapeutics Launches with EUR 25M Series A to Advance Lead Asset, Satoreotide, for the Treatment of Low- and High-Grade Neuroendocrine Cancers

Ariceum Therapeutics Launches with EUR 25M Series A to Advance Lead Asset, Satoreotide, for the Treatment of Low- and High-Grade Neuroendocrine Cancers

Oversubscribed financing co-led by HealthCap and EQT Life Sciences (formerly LSP); joined by Pureos Bioventures Developing novel drugs for systemic targeted radiation therapy (STRT) Proceeds will be used to advance lead radiopharmaceutical product, satoreotide, for the treatment of...

View More : https://www.prnewswire.com:443/news-releases/ariceum-therapeutics-launches-with-eur-25m-series-a-to-advance-lead-asset-s...

Releted News by prnewswire

Asetek Liquid Cooling Technology Powers NVIDIA® GeForce RTX™ 3090 Ti OC Edition GPU Cooler From ASUS ROG

Gaming Innovation Group signs a head of terms agreement with Crab Sports in Maryland

Cufflinks Market Size to Grow by USD 1.35 billion | Find Future Trends, Analysis, and Insights | Technavio

Ariceum Therapeutics Launches with EUR 25M Series A to Advance Lead Asset, Satoreotide, for the Treatment of Low- and High-Grade Neuroendocrine Cancers

ImaginAb and Roche have entered a clinical trial supply agreement for provision of atezolizumab (Tecentriq®)1 to Non-Small Cell Lung Cancer Patients Enrolled in ImaginAb's iPREDICT Phase IIb Study

DNS Abuse Institute Launches NetBeacon: First Ever Centralized DNS Abuse Reporting Service

True Cost of Fraud Soars as Cybercriminals Diversify